PlexusDx semaglutide review
Advertised at $129, billed at $189. Position 7 of 14 on our board.
Updated 2026-09-18
DISCLOSURE — Coreage Rx pays this desk a commission when a reader signs up through our link. It buys no ranking, no score and no deletions. Method: how we rate. Full terms: disclosure.
$189 a month for compounded semaglutide, no membership, same price at every dose.
Roughly $90 a month above the board floor. What the premium buys is a supply chain you can actually check.
The numbers
| PlexusDx · semaglutide | |
|---|---|
| Advertised | $129/mo |
| Membership | None |
| Billed | $189/mo |
| Advertised-to-billed gap | +$60/mo |
| Per year | $2,268 |
| Board position | 7 of 14, cheapest first |
No membership fee, and the price does not change as the dose is adjusted.
Where the gap is
Same "from $129" framing to watch. The injection tier is $189.
Against the board
About $2,268 a year against a $1,188 floor. Mid-board.
| Programme | Advertised | Billed | Gap | Vs board floor |
|---|---|---|---|---|
| Coreage Rx | $99 | $149 | +$50 | +$63/mo |
| Ozari Health | $86 | $86 | none | — |
| Trimi | $99 | $99 | none | +$13/mo |
| Zealthy | $151 | $151 | none | +$65/mo |
| Mochi Health | $99 | $178 | +$79 | +$92/mo |
| Hims & Hers | $79 | $188 | +$109 | +$102/mo |
| PlexusDx | $129 | $189 | +$60 | +$103/mo |
| Eden | $99 | $198 | +$99 | +$112/mo |
How the programme works
Prescription GLP-1 and peptide programmes with no membership fee, built around genetic testing, using independent clinicians and a publicly listed set of 503A pharmacies.
Verified facts
- GLP-1 weight-loss programmes start at $129/month.
- Compounded semaglutide injection listed at $189/month with no membership fee and the same price at every dose.
- A $189/month microdose tier is offered for compounded semaglutide or tirzepatide.
- No membership or platform fee is charged alongside the medication.
- Publicly names six 503A pharmacy partners: Belmar, Strive, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub and Foothills.
- Clinical oversight via LionMD, with named physicians and NPI numbers published.
- Licensed providers in all 50 states; CLIA-certified labs for its testing line.
Checked 2026-09-18. This market re-prices without notice — anything older than a month is a starting point, not a quote.
For it
- The most detailed pharmacy disclosure in this comparison — six named 503A partners.
- Names its prescribing physicians along with their NPI numbers.
- No membership fee, and flat pricing across the dose range.
- Genetic and blood testing available alongside the prescription.
Against it
- The genetics-led positioning adds cost and complexity some people will not want.
- The $129 figure is a programme floor rather than the injection price.
- Weight care sits alongside a broad longevity and supplement line rather than being the sole focus.
Read this bit. The advertised "from $129" is the programme floor. Budget $189/month for the compounded injection tier.
Score
4.4 out of 5 on our rubric, which is fixed before assessment and published on how we rate.
| Criterion | Weight | Score |
|---|---|---|
| True monthly cost | 30% | 4.6 / 5 |
| Price honesty | 20% | 4.5 / 5 |
| Clinical support | 20% | 3.8 / 5 |
| Pharmacy sourcing | 15% | 4.9 / 5 |
| Cancelling | 15% | 4 / 5 |
Verdict
Not competing on price. Competing on being checkable, and winning that.
More from the desk
- Coreage Rx semaglutide review
Advertised at $99, billed at $149. Position 1 of 14 on our board.
- Ozari Health semaglutide review
Advertised at $86 and billed at $86 — no gap. Position 2 of 14 on our board.
- Trimi semaglutide review
Advertised at $99 and billed at $99 — no gap. Position 3 of 14 on our board.
- Cheapest right now
Every programme sorted on what it bills, not what it advertises. Floor: $199/mo tirzepatide, $149/mo semaglutide.
- Six fee traps
Every advertised-to-billed gap on our board comes from one of these six structures. Learn them and you can read any of these sites in ninety seconds.
- Where the traps are
The biggest advertised-to-billed gaps on our board, and the programmes charging most for the same category of medication.